The development of new HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) offers the possibility of generating structures of increased potency. To this end, a series of 1-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-4-(1,1 -biaryl)-4-yl-piperazine derivatives (6a-l) was synthesized via the Suzuki coupling reaction. Analogously, coupling of the acid derivative 5, prepared from 4, with various amino acid methyl esters in the presence of HOBt/DCC reagents afforded the benzamide derivatives 8-11. The newly synthesized compounds were assayed against HIV-1 and HIV-2 in MT-4 cells. All compounds are inactive, except compound 6f which showed inhibition of HIV-1 with EC 50 = 2.60 µg mL −1 with a selectivity index (SI) of 9.
Introduction
Since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981, the human immunodeficiency virus (HIV)/AIDS has always been a global health threat and the leading cause of deaths [1] . Therefore, the rapid worldwide spread of AIDS has prompted an intense research effort to discover compounds that could effectively inhibit HIV. In the past two decades, 25 drugs, including nucleoside/nucleotide viral reverse transcriptase inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs) and fusion (or entry) inhibitors (FIs) were approved for clinical use [2] . Three NNRTIs, nevirapine [3] , delaviridine [4, 5] and efavirenz [6] , have been approved by the Food and Drug Administration (FDA) for the treatment of HIV infection. However, these drugs have only limited or transient clinical benefit. Therefore, the rapid emergence of resistant mutants against the NNRTIs allowed only a few compounds to reach the stage of clinical trials [7] . For this reason RT remains a central target in the development of anti-HIV-1 drugs, and of new classes of NNRTIs having high potency as well as being effective against resistant mutants [8, 9] .
Several potent heterocyclic NNRTIs have been synthesized with high anti-HIV inhibitory activity, some of which have an imidazole scaffold (for example, capravirine; S-1153, (1) (Fig. 1 ) [10] .
Several nitroimidazoles were reported to possess a number of biological activities, with possible applications as, e. g., antibacterial agents [11 -13] , potential radiosensitizers [14] , anticancer agents [15, 16] such as Dacarbazine R (DTIC) [17] and misonidazole [18] , fungicides and/or as antiprotozoal agents such as clotrinazole [1-(2-chlorotrityl)-1H-imidazole] [19, 20] and metronidazole (Flagyl) (2) [21] .
Some arylpiperazine derivatives possess antienterovirus activity [22, 23] , such as atevirdine (3) (Fig. 1 ) [24] and vicriviroc, which are currently in Phase II clinical trials [25] . In our recent work, we have reported new 4-nitroimidazoles with their anti-HIV activity [26 -32] ; meanwhile the efforts have been focused on developing inhibitors based on novel scaffolds, via a regioselective palladium(0)-catalyzed cross-coupling reaction [33, 34] . As a result of this strategy, new 4-nitroimidazole derivatives bearing substituted biphenylpiperazine and phenylbenzamide residues have been selected as a lead template in our present study which might lead to the optimization of HIV-1 RT inhibitory activity.
Results and Discussion
Our recent work [26 -31] has focused on the synthesis of 5-alkyamino, alkylsulfanyl and 2-alkylthio-1-piperazinyl derivatives of 4-nitroimidazoles as po- tentially active analogs. Scheme 1 depicts the chemistry employed in the preparation of this series of 5-substituted piperazinyl-4-nitroimidazole derivatives starting from 4 by replacement of the bromo substituent by 1-(4-bromophenyl)piperazine in hot DMF furnishing 5 (79 %). The Suzuki coupling reaction has been employed by using the bromo derivative 5 as a key intermediate for the synthesis of our target molecules and the appropriate arylboronic acids (e. g. phenyl-, 3-cyanophenyl-, 4-methylphenyl-, 3-methoxyphenyl-, 4-methoxyphenyl-, 4-fluoro-3-methoxyphenyl-, 3-fluoro-4-methoxyphenyl-, 3-aminophenyl-, 4-hydroxyphenyl-, 3-chloro-4-hydroxyphenyl-, pyrimidine-5-, and 5-indole boronic acid) in the presence of Pd(PPh 3 ) 4 and Na 2 CO 3 as catalysts to give 6a-l in 42 -73 % yield. Compounds 6a-l were prepared in a parallel way using a conventional method (longer reaction time, 3 -7 days), giving moderate yields and purity.
The structures of 6a-l were identified by 1 H, and 13 C NMR and mass spectra. The 1 H and 13 C NMR spectra of all prepared compounds are in agreement with the suggested structures. DEPT experiments were employed to differentiate secondary and quaternary carbons from primary and tertiary carbons. The 1 H NMR spectra showed rather similar patterns for the benzylic and ethyl protons. The two broad singlets at δ = 3.81 -3.52 and 2.98 -2.66 ppm were assigned to eight piperazine protons. The benzylic protons resonated at δ = 5.18 -5.14 ppm. In the 1 H NMR spectrum of 5, the protons 3 -H and 5 -H of the aromatic group at C(4) imidazole appeared as a doublet at δ = 6.99 ppm (J = 6.9 Hz), while 2 -H and 6 -H of the same group resonated as a doublet at δ = 6.74 ppm (J = 6.9 Hz). The signals of the biaryl protons were further identified by DFQ-COSY spectra [35] . The 13 C NMR spectra of 5 and 6a-l showed signals at δ = 150.6 -145.1 ppm, attributed to C(2) of the imidazole ring, while the carbon atoms C(4) and C(5) of the same ring resonated at δ = 145.4 -138.6 and 139.3 -135.5 ppm, respectively. The piperazine carbon atoms resonated at δ = 50.5 -49.1 and 49.4 -48.8 ppm, whereas the signals of the benzylic CH 2 carbon atoms appeared at δ = 46.6 -46.1 ppm. Compound 6b has been selected for further NMR studies, and its HMBC spectrum [36] revealed a 3 J C,H coupling between the methylene protons of piperazine at δ = 2.63 ppm and C(5) of the imidazole ring at δ = 138.6 ppm, as well as a 2 J C,H coupling with the carbons of piperazine at δ = 49.6 ppm. Additionally, a 3 J C,H coupling between methylene protons of piperazine at δ = 3.82 ppm and C-1 of the aromaic ring attached to the piperazine moiety at δ = 141.9 ppm was observed (Fig. 2) .
Additional support for the proposed structures comes from mass spectra which showed the correct molecular ions, (M + ), as suggested by their molecular formulas.
Next, treatment of 4 with 4-carboxy phenylboronic acid in the presence of Pd(PPh 3 ) 4 and Na 2 CO 3 as catalysts, using a Suzuki cross-coupling reaction and by following the method of Vanelle et al. [37] , afforded 5 in 72 % yield (Scheme 2).
Our work was modified by selecting 5 as a precursor for the synthesis of new benzamide derivatives to examine their antiviral activity in comparison to the biaryl analogs 6a-l. Thus, treatment of 7 with the acylated amino acid derivatives (glycine, L-serine, L-methionine, L-alanine and L-valine acetates) in the presence of HOBT and DCC as coupling reagents gave 8-11 in 74 % -67 % yield (Scheme 2).
The structures of 8-11 were determined by their 1 H, 13 matic residue at δ = 8.08 ppm. Similarly, C=O of the amide group at δ = 166.8 ppm was identified from its a 3 J C,H correlations to 3 -H and 5 -H of the aromatic residue at δ = 7.96 ppm (Fig. 3) , as well as a 3 J C,H correlation to the CHCH 2 OH proton at δ = 3.58 ppm. Additionally, The latter proton showed a 2 J C,H correlation to the CH 2 OH carbon atom at δ = 67.1 ppm (Fig. 3) . The mass fragmentation patterns were consistent with the suggested structures; however, the FAB-MAS spectra showed the protonated molecular ions of these compounds.
In-vitro anti-HIV assay
Compounds 5, 6a-l and 8-11 were tested for their in-vitro anti-HIV-1 (strain IIIB) and anti-HIV-2 (strain ROD) activity in human MT-4 cells using the MT-4/ MTT assay [38] . The results are summarized in Table 1, in which the data for azidothymidine (AZT) [39] and nevirapine (BOE/BIRG587) [40] are included for comparison purposes.
Compound 6f was found to be the only compound of the series inhibiting HIV-1 and HIV-2 replication in a cell culture, with an EC 50 value of > 2.60 µg mL −1 with a selectivity index (SI) of 9. Compound-induced cytotoxicity was also measured in MT-4 cells parallel with the antiviral activity.
Based on the chemical structure of compound 6f, this molecule can be proposed to act as non-nucleoside reverse transcriptase inhibitor (NNRTI).
6f
In conclusion, the data in Table 1 suggest that substitution of the bromo residue at position 4 of the nitroimidazole ring by a methoxy-fluoro-biphenyl group may engender an inhibitory activity on HIV-1.
Conclusion
In summary, a series of 5-(substituted-biphenyl-4-yl)piperazine (6a-l) and phenylbenzamide (8-11) derivatives of 1-benzyl-2-ethyl-4-nitroimidazole (4) were synthesized and evaluated in-vitro for their anti-HIV activity. Compound 6f exhibited moderate anti-HIV activity with SI = 9. Compound 6f, with a 4-fluoro-3-methoxyphenyl substituent, generally showed higher potency, and a dramatic change in activity was observed with congener 6g bearing a 3-fluoro-4-methoxyphenyl ring. Otherwise, compounds that were substituted at the aromatic ring by amino, cyano, hydroxy, methoxy, or methyl residues did not show any activity. Therefore, 6f is a promising agent for further structural modification and pharmacological evaluation.
Experimental Section

General
Melting points were measured on a Mettler FP1 melting point apparatus and are uncorrected. 1 H NMR and 13 C NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K.
NMR spectra were recorded on 400 and 500 MHz ( 1 H) and on 150.91 MHz ( 13 C) spectrometers (Bruker, Germany) with TMS as internal standard and on the δ scale in ppm. Signal assignments for protons were performed by selective proton decoupling or by COSY spectra. Heteronuclear assignments were verified by 1 H-13 C COSY or HMBC experiments. All coupling constants (J) are given in Hz. Mass spectra (ESI) were recorded on a TSQ Quantum (Thermo Fisher) instrument and a MAT 8200 spectrometer (Finnegan MAT, USA). Microwave-assisted reactions were carried out in a CEM focused microwave synthesis system (100 -150 W). Purification of products was performed by preparative thinlayer chromatography (TLC) using 1 mm SIL G-100 UV 254 glass plates (Macherey-Nagel), and the progress of the reaction was monitored by TLC on Alugram SIL G UV 254 (Macherey-Nagel).
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)4-(4-bromophenyl)piperazine (5)
To a stirred solution of 4 (3.10 g, 10.0 mmol) in DMF (25 mL) was added 1-(4-bromophenyl)piperazine (1.03 g, 12.0 mmol), and the solution was heated at 70 -80 • C for 6 h. The solution was evaporated to dryness, the residue was washed with diethyl ether and purified by TLC using CHCl 3 
General procedure for preparation of 1-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-4-(1,1 -biaryl-4-yl)piperazines 6a-l
A suspension of 5 (235 mg, 0.50 mmol), substituted arylboronic acid (0.70 mmol), tetrakis(triphenylphosphane)-palladium (Pd(Ph 3 ) 4 ) (22 mg, 5 % mmol), and Na 2 CO 3 (212 mg, 2.00 mmol) in DMF-water 1 : 1 (40 mL) was heated at 70 -80 • C for 6 h or under MWI for 30 min. After cooling, the mixture was evaporated to dryness, and the residue was partitioned between ethyl acetate (3 × 30 mL) and water (30 mL). The combined organic extracts were dried (Na 2 SO 4 ) and filtered. The filtrate was evaporated to dryness, and the crude product was purified by preparative TLC.
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-(1-[1,1 -biphenyl]-4-yl)piperazine (6a)
From phenylboronic acid (85 mg 
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-4-(3 -isocyano-[1,1 -biphenyl]-4-yl)piperazine (6b)
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-4-(4 -methyl-[1,1 -biphenyl]-4-yl)piperazine (6c)
From
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-4-(3 -methoxy-[1,1 -biphenyl]-4-yl)piperazine (6d)
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-4-(4 -methoxy-[1,1 -biphenyl]-4-yl)piperazine (6e)
4-(4-(4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl)phenyl)pyrimidine (6k)
From pyrimidine-5-boronic acid (87 mg, 0.70 mmol 
5-(4-(4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl)phenyl)-1H-indole (6l)
4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)benzoic acid (7)
This compound was prepared according to the procedure for the preparation of 5 from 4 (618 mg, 2.00 mmol) and 4- (8) (9) (10) (11) General procedure. -To a cold solution of the amino acid ester (2.0 mmol) at −5 • C in MeCN (20 mL), 7 (703 mg, 2.0 mmol), hydroxybenzotriazole (HOBt) (270 g, 2.0 mmol) and N, N -dicyclohexyl-carbodiimide (DCC) (412 mg, 2.00 mmol) were added successively. The reaction mixture was stirred at 0 • C for 1 h, at 5 • C for 1 h, and at 23 • C for 16 h. Dicyclohexylurea (DCU) was filtered off, and the filtrate was evaporated to dryness. The residue was dissolved in ethyl acetate, and the solution was filtered and washed successively with saturated NaCl solution, 5 % NaHCO 3 solution, 1 M HCl, followed by washing with saturated NaCl solution and finally with water. The solution was dried (Na 2 SO 4 ), filtered, evaporated to dryness and the residue purified on a SiO 2 column to give the desired products.
Synthesis of 4-nitroimidazoles bearing amino acid esters
